 Prostate Cancer patients treated with LHRH agonists e.g., goserelin lose Bone Mineral Density BMD. Using a prospective, observational study design, we propose that monitoring how physicians manage Cancer Treatment Induced Bone LossCTIBL in their patients. The gold standard for evaluating BMD is dual energy x-ray absorptiometry DEXA. The proposed study will provide some of the first prospective data on the rates of Skeletal Related Events SREs in prostate cancer patients undergoing ADT and help develop official guidelines on the use of DEXA screening for prostate cancer patients. 